Please Wait...

  • +91 22 2783 1455

  • Product background
    LAVINA CEFUROXIME FOR INJECTION (Cefuroxime for Injection USP 750 mg)

WARNING: CAUTION : PLEASE NOTE :
The content or product detailing is not intended to replace advice from your prescribing doctor or healthcare professional. Lavina Pharma is not responsible for such actions by consumers. For any further information about the product please contact +91 22 2783 1455 and we can provide you the details.

Cefuroxime sodium for injection is indicated for the treatment of infections listed below in adults and children, including neonates (from birth).

·      Community acquired pneumonia

·      Acute exacerbations of chronic bronchitis

·      Complicated urinary tract infections, including pyelonephritis

·      Soft-tissue infections: cellulitis, erysipelas and wound infections

·      Intra-abdominal infections

·      Prophylaxis against infection in gastrointestinal (including oesophageal), orthopedic, cardiovascular, and gynecological surgery (including caesarean section)

In the treatment and prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents.

        Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Ceftriaxone is a powerful, broad-spectrum antibiotic used to treat a wide range of bacterial infections in adults, children, and even term neonates. It is effective in managing conditions such as meningitis, pneumonia, urinary and intra-abdominal infections, joint and bone infections, skin infections, and ear infections.

It also treats sexually transmitted infections like gonorrhoea and syphilis, bacterial endocarditis, and Lyme disease. Additionally, Ceftriaxone is used in managing COPD flare-ups and for pre-operative prevention of surgical site infections. Side effects may include gastrointestinal discomfort, allergic reactions, or pain at the injection site.


COMPOSITION

Each vial contains:

Cefuroxime Sodium USP (Sterile)

Eq. to Cefuroxime ………….. 750 mg

Intramuscular administration/ Intravenous administration

DOSAGE

As directed by the physician

SIDE EFFECT

·        Neutropenia, eosinophilia, decreased haemoglobin concentration Diarrhoea

·        Transient rise in liver enzymes Indigestion

·        Injection site reactions which may include pain and thrombophlebitis

·        Gastrointestinal disturbance





PRECAUTION

As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics.

Due to its spectrum of activity, cefuroxime is not suitable for the treatment of infections caused by Gram-negative non-fermenting bacteria.

Antibacterial agent–associated pseudomembranous colitis has been reported with use of cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime. Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.




PRESENTATION

50 glass vials of 10 mL packed in a carton along with pack insert.